Business Wire

  1. Redwire Awarded NASA Contract To Expand Pharmaceutical Drug Development In Space For Future Commercialization 3/25/2025

    Redwire Corporation, a leader in space infrastructure for the next-generation space economy, has been awarded a NASA contract to launch four additional pharmaceutical drug investigations to the International Space Station using the company’s innovative Pharmaceutical In-space Laboratory (PIL-BOX).

  2. SOLVE FSHD Announces Strategic Collaboration With Transcripta Bio To Advance Drug Discovery For FSHD 3/25/2025

    SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), is pleased to announce a strategic collaboration with Transcripta Bio, a cutting-edge AI-driven drug discovery company.

  3. ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation For RCT2100 For The Treatment Of Cystic Fibrosis 3/25/2025

    ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for RCT2100, a novel, investigational mRNA therapy being developed to treat cystic fibrosis (CF).

  4. Charles River And Valo Health Identify A Potential Therapeutic For Lupus Using Logica, An AI-Powered Drug Discovery Platform 3/25/2025

    Charles River Laboratories International, Inc. and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need.

  5. Sapio Sciences Makes AI-Native Drug Discovery Seamless With NVIDIA BioNeMo 3/19/2025

    Sapio Sciences, the science-aware lab informatics platform, today announced the integration of the NVIDIA BioNeMo platform into the Sapio Lab Informatics Platform.

  6. Valo Health And nference Announce Long-Term Partnership To Accelerate Human-Centric Drug Discovery And Development 3/18/2025

    Valo Health, Inc. (“Valo”), a biotechnology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence (AI), today announced a multi-year collaboration with nference, a company dedicated to transforming healthcare by making biomedical knowledge computable.

  7. Precision BioSciences Announces Clearance Of Investigational New Drug Application By The U.S. FDA For First-In-Class PBGENE-HBV Designed To Eliminate Root Cause Of Chronic Hepatitis B 3/17/2025

    Precision BioSciences, Inc., a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PBGENE-HBV.

  8. Xeris Announces Approval Of Supplemental New Drug Application (sNDA) Of Gvoke VialDx (Glucagon) For Use As A Diagnostic Aid 3/17/2025

    Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that its supplemental new drug application (sNDA) of Gvoke VialDx has received U.S Food and Drug Administration (FDA) approval for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

  9. LGM Pharma Invests $6M In U.S. Drug Manufacturing Capabilities For Liquids, Suspensions, Semi-Solids, And Suppositories 3/12/2025

    LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product lifecycle, today announced an investment of over $6M to expand its Rosenberg, Texas manufacturing facility as part of its Phase I CDMO growth strategy.

  10. Sydnexis Announces FDA Acceptance Of New Drug Application For SYD-101 For The Treatment Of Progression Of Pediatric Myopia 3/11/2025

    Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for SYD-101 and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 23, 2025.